Corporate Secretary, TransCelerate; VP, Global Medical Affairs, Eli Lilly and Company
Robert Baker is a Vice President of Eli Lilly and Company and wears several hats (May 2020):
- Leader of the Design Hub. This cross-functional group sited within Lilly’s Clinical Development Organization serves as a center of expertise in designing and planning delivery of clinical trials for all therapeutic areas. For prioritized or novel programs, the Hub partners with the molecule teams in identifying options for the development program, ideally including novel approaches, and the hub’s statisticians perform Lilly’s outcome modelling and simulations. For all Lilly trials the hub leads planning functions such as protocol writing, country and investigator selection, budgeting, advertising, and investigator training.
- Leader for Exploratory Medicine and Pharmacology. This group includes the physicians and scientists who design and hold medical accountability for Lilly’s Phase I (excluding oncology) and Biopharmaceutical work; the clinical operations teams executing these studies; and Lilly’s clinical pharmacology center in Singapore (an inpatient and outpatient facility for much of Lilly’s work in healthy volunteers, with particular expertise in first-in-man and insulin/glucose clamp studies).
- Chair, Development Advisory Council. The council is comprised of Lilly’s senior development leaders and is responsible for recommendations to Lilly’s executive committee for decisions on large clinical funding commitments.
Robert has been at Lilly for 20 years in various roles across Development, Drug Safety, and Medical Affairs, including various previous vice president roles: leading Phase 2B-4 Development for Psychiatry, Pain, and Sleep; leading Global Medical Affairs (including strategic accountability for assets outside Diabetes and Oncology plus oversight of the Medical Teams in Lilly’s US, Canada, Australia, and European Affiliates); and leading Global Patient Safety for the clinical portfolio. He has served as Co-Chair of PhRMA’s Clinical and Pre-Clinical Development Committee and as a work group leader for TransCelerate’s pharmacovigilance efforts. Currently Robert is the industry representative to FDA’s Psychopharmacologic Drugs Advisory Committee.
Prior to joining Lilly, Dr. Baker spent a dozen years as an Academic Psychiatrist studying schizophrenia and substance abuse. He completed medical school at Northwestern University and psychiatry training at the University of Pittsburgh.